gene_symbol
HLA-DQA1
hgnc_id
HGNC:4942
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes neoantigen-specific T cells; activated CD8+ T cells kill tumor cells presenting neoantigen peptides on MHC I via perforin/granzyme or Fas–FasL. HLA-DQA1 (MHC II) on APCs is used for presentation, not targeted for killing.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Forms HLA-DQ with HLA-DQB1; presents peptides to CD4+ T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06751966
disease_id_num_tar_ref
5988
drug_id_num_tar_ref
16236